BUD vs KPTI
BUD (BUD) versus Karyopharm Therapeutics Inc (KPTI) — a side-by-side from cached financials, not a winner call.
BUD (BUD) common stock.
Karyopharm Therapeutics Inc (KPTI) is a biotechnology company listed on US.
BUD does not have a complete income-statement cache yet.
Latest reported KPTI revenue for 2026-06-30 was $68.5M. Net income was -$89.4M. Revenue was up 95.3% from 2026-03-31 to 2026-06-30. KPTI currently screens at market cap $205.6M.
BUD currently screens at market cap $0. KPTI currently screens at market cap $205.6M.
Not investment advice. Open the BUD and KPTI stock pages for the full models.
Not investment advice.